CGEM – cullinan oncology, inc. (US:NASDAQ)
Stock Stats
News
Cullinan Therapeutics (NASDAQ:CGEM) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at BTIG Research.
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at Wall Str
Cullinan Therapeutics (NASDAQ:CGEM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Form 4 Cullinan Therapeutics, For: Nov 24 Filed by: Michaelson Jennifer
Form 144 Cullinan Therapeutics, Filed by: Michaelson Jennifer
Form 8-K Cullinan Therapeutics, For: Nov 18
Form SCHEDULE 13G/A Cullinan Therapeutics, Filed by: CITADEL ADVISORS LLC
Form SCHEDULE 13G/A Cullinan Therapeutics, Filed by: Lynx1 Capital Management LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.